TrialThe Journal of clinical investigation2024

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.

Jacob Appelbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.